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Abstract
Background: The newly discovered metastasis-associated in colon cancer-1 (MACC1) gene is a key regulator of the
HGF/MET pathway. Deregulation of HGF/MET signaling is reported as a prognostic marker for tumorigenesis, early
stage invasion, and metastasis. High expression levels of MACC1 have been associated with colon cancer
metastasis and reduced survival. Potential links between the genetic diversity of the MACC1 locus and overall
survival are unknown. We therefore investigated the association between MACC1 tagging single nucleotide
polymorphisms (SNPs) and overall survival in a large cohort of colorectal cancer patients.
Methods: The study included 318 subjects with histopathologically proven colorectal cancer at the Academic
Teaching Hospital Feldkirch, Austria. Survival data were provided by the federal agency for statistics in Austria.
Genomic DNA was isolated from formalin-fixed paraffin-embedded specimens; six tagging SNPs (rs1990172,
rs3114446, rs10275612, rs3095007, rs3095009, and rs7780032), capturing most of the common variants of the
MACC1 locus, were genotyped by SNaPshot assays.
Results: Over a mean follow up period of 5.3 (± 1.0) years, 94 deaths were recorded. Carriers of the G-allele of SNP
rs1990172 showed a significantly decreased overall survival (additive HR = 1.38 [1.05-1.82]; p = 0.023). Multivariate
analysis adjusted for age and UICC tumor stage confirmed this result (HR = 1.49 [1.12-1.98]; p = 0.007). Other
investigated genetic variants of the MACC1 gene were not significantly associated with overall survival (p-values >
0.05).
Conclusions: For the first time, our study investigated the influence of MACC1 tagging polymorphisms on overall
survival suggesting SNP rs1990172 as a predictor for reduced overall survival in colorectal cancer patients. Further
studies will be required to validate our findings.
Background
Colorectal cancer (CRC) is one of the most frequent
malignancies in the Western world and one of the lead-
ing causes of cancer related deaths [1,2]. Metastatic dis-
semination of primary tumors is directly linked to
patient’s survival and accounts for about 90% of all CRC
deaths [3]. Local invasion and the formation of metas-
tases are clinically the most relevant processes involved
in carcinogenesis, but their molecular mechanisms are
not fully understood. There is growing evidence that the
genetic heterogeneity of CRC has a major influence on
its prognosis and the search for adequate molecular
prognostic markers has come into focus of translational
cancer research.
A significant success in this effort has been the identi-
fication of the metastasis-associated in colon cancer-1
(MACC1) gene as a crucial prognostic factor for CRC
metastasis, as recently reported by Stein and colleagues
[4]. The previously undescribed gene MACC1 (formerly
designated as 7a5) was discovered by a genome-wide
search for differently expressed genes in human colon
cancer tissues, metastases, and normal tissues. In this
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tively with colon cancer metastasis and reduced metas-
tasis-free survival [4]. Further, subsequent studies have
shown that overexpression of MACC1 is associated with
poor disease-free survival in patients with gastric carci-
noma [5] and lung adenocarcinoma [6], respectively,
a n di tw a sf o u n dt h a tM A C C 1i sm o r ef r e q u e n t l y
expressed in vascular invasive hepatocellular carcinoma
[7]. These findings suggest that MACC1 may serve as a
new parameter for the prognostic prediction of different
kinds of cancer.
MACC1 acts as a master regulator of HGF-MET sig-
naling pathway [4,8], whose activation has been found
to play a critical role in oncogenesis and cancer metasta-
sis [9,10]. Consequently, MET overexpression has been
associated with poor clinical outcome [11,12]. Clinical
studies of the therapeutic efficacy of MET-inhibitors in
metastatic CRC are ongoing. Of note, it has been shown
that overexpression of MACC1 correlates better with
unfavourable pathologic features than overexpression of
MET. Moreover, bioinformatic analysis of putative
MACC1 targets identified elements besides MET, whose
overexpression cosegregated with aggressive forms of
CRC [13]. These data indicate that MACC1 could con-
tribute to CRC progression through mechanisms other
than or additional to MET transcriptional upregulation.
The MACC1 gene is located on chromosome 7 at
position 7p21.1. Gain of chromosome 7 or selective gain
of the p-arm is a relatively frequent occurrence in CRCs
[13,14]. These chromosomal alterations might provide a
link to the mechanisms leading to induced MACC1
expression. Further, numerous single nucleotide poly-
morphisms (SNPs) have been discovered in the human
MACC1 gene (http://www.ncbi.nlm.nih.gov/projects/
SNP). Some of these genetic variants may also contri-
bute to altered MACC1 expression or function and as a
consequence influence the prognosis of CRC. However,
the impact of MACC1 SNPs on the clinical outcome of
CRC has not been investigated yet.
We therefore investigated the association between
MACC1 tagging SNPs capturing the majority of
common alleles at the MACC1 locus and overall survi-
val in a large cohort of colorectal cancer patients.
Methods
Patients
The present study included 318 white patients with his-
tologically proven colorectal cancer diagnosed at the
Department of Pathology at the Academic Teaching
Hospital Feldkirch, Austria, from January 2003 to Octo-
ber 2006. All tumours were graded by an experienced
pathologist using 6th edition of UICC classification [15].
After appropriate investigational review board approval,
formalin fixed, paraffin embedded (FFPE) tissue blocks
were recovered. Follow-up survival data were provided
by the Federal Agency for Statistics in Austria. The
Ethics Committee of the Land Vorarlberg, Austria,
approved the present study.
SNP Selection
Six tagging SNPs (rs1990172, rs3114446, rs10275612,
rs3095007, rs3095009, and rs7780032) were selected
from the HapMap SNP database [16], release #27; analy-
sis panel: CEU + TSI (Utah residents with ancestry from
Northern and Western Europe as well as Tuscan resi-
dents in Italy), using as criteria a minor allele frequency
(MAF) ≥ 0.15 and pairwise r
2 ≥ 0.8 according to Tagger
software [17] implemented in Haploview program [18].
According to HapMap SNP database, these tagging
SNPs capture 75% of variants with a MAF ≥ 0.15 within
a region comprising 94 kb of chromosome 7, position
20,140,000 to 20,234,000 (NCBI build 36, hg18), includ-
ing approximately 11 kb 5’-flanking and 6 kb 3’-flanking
sequences of the MACC1 gene. The genomic positions
of selected MACC1 SNPs are shown in Figure 1. All six
tagging SNPs are located in intronic regions.
Genotyping
Genomic DNA was extracted from deparaffinized FFPE
tissue samples using the peqGOLD
® Tissue DNA Mini
Kit (PEQLAB Biotechnologie Ltd., Erlangen, Germany)
according to the manufacturer’s instructions.
Figure 1 Genomic positions of selected MACC1 tagging SNPs. MACC1 is located on the minus strand of chromosome 7. The MACC1
contains seven exons (E1-E7) and six introns. Coding regions are shown as black boxes and non-coding exons as white boxes. Positions of the
genotyped MACC1 SNPs are relative to the first nucleotide of the MACC1 gene as given in the NCBI reference sequence NT_079592.2. All
selected SNPs are located in intronic regions.
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SNaPshot
® method (Applied Biosystems, Forster City,
CA) consisting of PCR and multiplexed single-base
extension, followed by capillary electrophoresis, as
described in Additional file 1 ("Genotyping of MACC1
SNPs by the SNaPshot
® method”). In brief, genetic
regions flanking the SNP of interest were amplified by
PCR. PCR-products were used in a multiplex single-base
primer extension reaction using the SNaPshot Multiplex
Kit (Applied Biosystems), according to the manufac-
turer’s protocol. PCR primer sequences and extension
primer sequences are given in Additional file 2: Table
S1 and Additional file 3: Table S2 respectively. Finally,
labeled extension products were resolved by capillary
electrophoresis on an ABI 3130 DNA Analyzer (Applied
Biosystems) and data analysis was performed using Gen-
eMapper Analysis Software version 4.0 (Applied Biosys-
tems). Further, genotyping of 20 randomly selected
samples was performed by Sanger sequencing to assess
quality of SNP genotyping.
Statistical analysis
Overall survival time was calculated from the time of
histopathological diagnosis to death from any cause or
the last follow up, at which point survival data were col-
lected. Hazard ratios (HR) and 95% confidence intervals
(CI) of the hazard ratios were derived from univariate
and multivariate Cox proportional hazards models. Sur-
vival curves were generated using the Kaplan-Meier
method and compared using the Log-Rank-Mantel-Cox-
Test. Observed numbers of each genotype were com-
pared with those expected to test whether the sample
was in Hardy-Weinberg equilibrium using the Chi-
Square test with one degree of freedom. To measure
linkage disequilibrium, the squared correlation coeffi-
cient r
2 was calculated for each pair of SNPs using
CubeX software (http://www.oege.org/software/cubex
[19]). P-values < 0.05 were considered as significant. Sta-
tistical analyses were performed with the software pack-




Over a mean follow up period of 5.3 (SD ± 1.0) years,
94 deaths were recorded, thus 29.6% of the patients
died. The patient characteristics at baseline with respect
to overall survival are presented in Table 1. Age at can-
cer diagnosis and UICC stage were significantly asso-
ciated with overall survival.
Results from genotyping
Genotypes were successfully called in 302 patients for
SNP rs3095007 (95.0%), in 307 patients for SNP
rs7780032 (96.5%), in 311 patients for SNP rs3095009
(97.8%), and in 318 patients for SNP rs3114446,
rs1990172, and rs10275612 (100%), respectively. Results
of re-genotyping analysis of 20 randomly selected sam-
ples were 100% in agreement with the initial genotyping
results. Observed MAFs and genotyping frequencies as
well as results from Hardy-Weinberg disequilibrium
analysis are presented in Additional file 4: Table S3.
MAFs were similar to those given in HapMap SNP data-
base [16] for a CEU + TSI analysis panel and all six
MACC1 SNP genotype frequencies did not deviate sig-
nificantly from Hardy-Weinberg equilibrium. SNPs were
in low linkage disequilibrium or did not show any link-
age disequilibrium (r
2 r a n g i n gf r o m0 . 4 5t o0 ,a sp r e -
sented in Additional file 5: Table S4); therefore, no
further haplotype analysis was conducted.
Association of determined MACC1 SNP genotypes with
overall survival
Impact of included MACC1 SNPs and overall survival
was evaluated by univariate Cox regression analysis
using an additive model of inheritance. Results are pre-
sented in Figure 2. Among investigated SNPs, variant
rs1990172 was significantly associated with an increased
risk for any death. Remaining SNPs of the MACC1
locus did not show a significant impact on overall
survival.
The impact of variant rs1990172 on overall survival
was further assessed by univariate and multivariate Cox
regression analysis, adjusting for age und UICC stage,
using an additive, dominant, and recessive model of
Table 1 Patient characteristics with respect to overall
survival
Overall survival
n HR (95% CI) p-value
Age <60 62 1
60-70 104 2.28 [0.99-5.27] 0.054
>70 152 2.09 [1.41-3.09] <0.001
Gender Female 141 1
Male 177 1.21 [0.80-1.83] 0.357
UICC stage Stage I 64 1
Stage II 128 2.15 [1.03-4.47] 0.041
Stage III 97 1.67 [1.16-2.42] 0.006
Stage IV 29 1.81 [1.30-2.37] <0.001
Grade score* G1 93 1
G2 193 1.09 [0.69-1.71] 0.723
G3-4 28 1.14 [0.78-1.67] 0.504
Tumor localisation ** Colon 219 1
Rectal 88 1.39 [0.91-2.13] 0.127
*Grade score, missing samples: n = 4; Tumor localisation, missing samples: n =
11
Hazard ratios (HR) and 95% confidence intervals (95% CI) were obtained from
univariate Cox regression analysis
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2.
In an additive and dominant model of inheritance,
carriers of the G-allele of SNP rs1990172 showed a sig-
nificantly increased risk for reduced overall survival, in
both, univariate and multivariate Cox regression analy-
sis. A recessive model in univariate Cox regression ana-
lysis did not reach statistical significance, but became
significant after adjustment for age und UICC stage.
Additionally, Kaplan-Meier survival curves were gra-
phically displayed according to an additive, dominant,
and recessive model of inheritance (Figure 3). Again,
SNP rs1990172 was significantly associated with overall
survival under an additive and dominant model of
inheritance.
Discussion
In the present work, we report the novel finding of a
positive association of the MACC1 tagging SNP
rs1990172 with reduced overall survival in patients with
CRC. To our best knowledge this is the first study
investigating the influence of MACC1 polymorphisms
on the prognosis of CRC. Several studies have investi-
gated the influence of MACC1 mRNA levels on the
clinical outcome in patients with colorectal [4], gastric
[5] and lung cancer [6], respectively, providing evidence
that MACC1 overexpression is a crucial prognostic fac-
tor for tumor recurrence, metastasis, and survival. Our
finding that a tagging SNP in the MACC1 gene is signif-
icantly associated with patient’s survival indicates that
beside MACC1 mRNA levels also the genetic diversity
o ft h eM A C C 1l o c u si n f l u e n c e st h ep r o g n o s i so fC R C .
Therefore, our results emphasize the relevance of
MACC1 as a prognostic marker also at the DNA level
for clinical outcome prediction.
Overexpression of MACC1 may be caused by aneu-
ploidy of chromosome 7, where MACC1 is located
(position 7p21.1). Indeed, as shown by Galimi and col-
leagues [13], expression of MACC1 correlates with
polysomy of chromosome 7 or with ploidy of the p-arm
in metastatic CRC. However, in this study polysomy of
Figure 2 Influence of determined MACC1 tagging SNPs on overall survival shown for an additive genetic model of inheritance. Hazard
ratios and 95% confidence intervals were obtained from univariate Cox regression analysis.
Table 2 Impact of MACC1 SNP rs1990172 on overall
survival, shown for dominant, recessive, and additive
genetic models of inheritance
Genetic model Adjustment model HR 95%CI P-value
Additive Model 1 1.38 1.05-1.82 0.023
Model 2 1.49 1.12-1.98 0.007
Dominant Model 1 1.59 1.05-2.40 0.028
Model 2 1.63 1.08-2.47 0.020
Recessive Model 1 1.50 0.86-2.60 0.152
Model 2 1.82 1.04-3.18 0.036
Hazard ratios (HR) and 95% confidence intervals (95% CI) were obtained from
univariate Cox regression analysis (model 1) and multivariate Cox regression
analysis adjusting for age and UICC stage (model 2)
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at a low-level, with an average of 3.3 and 3.4 copies,
respectively. Other, yet unknown molecular mechanisms
may also contribute to MACC1 overexpression or func-
tion. SNPs located in coding or regulatory sequences
have the potential to modify the biological activity of
MACC1. Several putative deleterious SNPs are located
at the MACC1 locus: One SNP leads to a premature
stop codon at residue 390 (rs2108292) and two SNPs
(rs36106647, rs35043094) shift the reading frame after
amino acid 670, leading to a translational stop codon
after 11 additional residues [20]. However, according to
NCBI SNP database (http://www.ncbi.nlm.nih.gov/pro-
jects/SNP), these genetic variants are rare and will cause
low statistical power, especially if penetrance is low, or
even might be absent in a patient cohort of limited sam-
ple size. On the other hand, hundreds of common var-
iants at the MACC1 locus of still unknown function are
listed in the NCBI SNP database. Selection of a set of
tagging SNPs based on stringent criteria like a high r
2
value allows covering most of this given genetic variance
[21].
Here, we report the significant association of the
MACC1 tagging SNP rs1990172 with reduced overall
survival in CRC patients. Variant rs1990172 is located
within an intronic region of the MACC1 gene (Figure 1)
and does not affect any splice site of a coding exon.
Therefore, it is unclear, if rs1990172 is the causative
SNP responsible for the observed effects. Notably, the
variant is in strong linkage disequilibrium with a non-
synonymous SNP, rs975263 (r
2 = 0.858; http://www.hap-
map.org), which is leading to an exchange of leucine to
serine at codon 515, fifth exon. However, in silico analy-
sis using software tools PolyPhen-2 (http://genetics.bwh.
harvard.edu/pph2) [22] and SIFT (http://sift.jcvi.org)
[23], respectively, does not suggest an adverse impact of
this amino acid substitution on the structure or function
of the MACC1 protein (data not shown). Both SNPs are
located in a large haplotype spanning at least 50 kb of
the MACC1 sequence, comprising three coding exons of
the MACC1 gene. This indicates that also other SNPs in
this haplotype may contribute to the prognosis of CRC.
Of note, according to data of HapMap recombination
rates [24], two strong recombination hotspots outside
the MACC1 locus around positions 20,091,000 and
20,607,000 (NCBI build 36) are defining a huge haplo-
type block including beside MACC1 another metasta-
sis-associated gene, namely ITGB8 [25]. Therefore, an
association between a SNP within the MACC1 locus
and the clinical outcome might be linked to its corre-
lation to causal genetic variants of the ITGB8 locus
(position 20,337,000-20,420,000, NCBI build 36). How-
ever, linkage disequilibria between SNPs in the
MACC1 and ITGB8 loci are at best of weak extend (e.
g. r
2 values between rs1990172 and SNPs within the
ITGB8 locus ranging from 0.00 up to 0.089; http://
www.hapmap.org). Consequently, observed effect of
the tagging SNP rs1990172 on overall survival appears
p r e d o m i n a n t l yc a u s e db yt h eg e n e t i cd i v e r s i t yo ft h e
MACC1 gene.
Figure 3 Results from Kaplan-Meier analysis: Influence of MACC1 SNP rs1990172 on overall survival. Kaplan-Meier curves are shown for
an additive (a), dominant (b), and recessive model (c) of inheritance. P-values were calculated by Log-rank tests.
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rs3095009, and rs7780032 were not associated with
overall survival. These variants are all located in non-
coding or non-regulatory regions and are not in high
linkage disequilibrium with any functional SNP given in
HapMap SNP database [16]. Therefore, among investi-
gated SNPs, variant rs1990172 remains the only one
which is linked to a potentially functional region, which
might explain the fact that among investigated SNPs
solely rs1990172 is significantly associated with the
prognosis of CRC.
In vitro studies have shown that MACC1 acts a key
regulator of its transcriptional target gene MET [4,8],
which encodes for the Met tyrosine kinase receptor for
hepatocyte growth factor (HGF) [9]. Aberrant activation
of MET deregulates the HGF/MET signaling pathway,
leading to increased cell proliferation, invasion, and
metastasis [9,10]. Consequently, high expression of MET
in colorectal cancers is linked to the development of dis-
tant metastases and represents a strong prognostic indi-
cator for poor survival [11,12]. These findings have led
to the development of agents that can effectively disrupt
HGF/MET signaling through direct inhibition of the
receptor (anti-MET antibodies), through inactivation of
its ligand HGF, by interfering with HGF binding to
MET, or by inhibiting MET kinase activity [26]. Several
phase I and II clinical trials addressing the therapeutic
efficacy of these agents are currently under way. Ampli-
fication of the MET gene responds to Met inactivation
with growth impairment gene in vitro and may therefore
predict treatment outcome in vivo [13]. In a similar way,
functional SNPs at the MACC1 locus associated with
MACC1 activity or function may act as easily detectable
predictive markers in anti-HGF/MET treatment in the
future.
It is important to consider the potential limitations of
our study. Overall survival was defined as the sole clini-
cal end point evaluated. MACC1 is associated with
colon cancer metastasis. Therefore, metastasis-free sur-
vival would represent a more accurate endpoint. How-
ever, the metastatic process is directly linked to patient
survival [3] and, therefore, our observation that a
MACC1 polymorphism is significantly associated with
reduced overall survival also indicates its role in meta-
static dissemination. Selected tagging SNPs captured
75% of variants with a MAF ≥ 0.15 and, therefore, 25%
of common SNPs remained unexplored. Further, less
frequent polymorphisms (MAF <0.15) were not consid-
ered by selection criteria. However, it is questionable if
a probably moderate association between a polymorph-
ism of low frequency and overall survival would have
reached statistical significance due to given sample size.
Further, it remains unclear, if the tagging variant
rs1990172 or another variant, which is highly correlated
with it, is the causative SNP responsible for the
observed effects. Additional studies, such as fine map-
ping studies and directed functional studies to deter-
mine the molecular consequences of genetic variation at
this locus are needed. Finally, we have not accounted
for multiple testing in our study. Of note, the Bonfer-
roni correction would probably have been too conserva-
tive owing to the given correlation among the tests
performed. Therefore, associations between rs1990172
and clinical outcome appear significant only at a nom-
inal significance level. Notably, the observed significant
association between variant rs1990172 and overall survi-
val would have survived Bonferroni correction in the
adjusted additive model of inheritance (pcorrected =
0.042). Replication of our observations in independent
studies is necessary to clarify the prognostic relevance of
MACC1 polymorphisms to the clinical course of CRC.
Conclusion
Our study provides the first results that the genetic
diversity of the MACC1 locus is associated with overall
survival in colorectal cancer patients. The result of our
study emphasizes the clinical relevance of MACC1 as a
prognostic marker gene, which may help to select high-
risk patients for more aggressive treatment strategies.
Further studies are warranted to validate these findings.
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